BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6227629)

  • 1. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
    J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
    Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
    Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
    Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; Smith IE
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
    Samojlik E; Santen RJ; Wells SA
    J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
    [No Abstract]   [Full Text] [Related]  

  • 10. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
    Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
    J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
    Samojlik E; Santen RJ
    J Clin Endocrinol Metab; 1980 Sep; 51(3):462-5. PubMed ID: 6447707
    [No Abstract]   [Full Text] [Related]  

  • 14. Aminoglutethimide in the treatment of advanced breast cancer.
    Stuart-Harris RC; Smith IE
    Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
    [No Abstract]   [Full Text] [Related]  

  • 15. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
    Worgul TJ; Santen RJ; Samojlik E; Wells SA
    J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings.
    Kahán Z; Tóth I; Vecsernyés M
    Oncology; 1992; 49(1):31-4. PubMed ID: 1542490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
    van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
    Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
    Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
    Newsome HH; Brown PW; Terz JJ; Lawrence W
    Surgery; 1978 Jan; 83(1):83-9. PubMed ID: 619476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
    Samojlik E; Santen RJ
    J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.